Please check your internet connection and try again.
# Ecospirin (Aspirin Enteric-Coated)
## Overview
Ecospirin is an enteric-coated formulation of aspirin, a nonsteroidal anti-inflammatory drug (NSAID) with analgesic, antipyretic, and antiplatelet properties. The enteric coating is designed to delay the release of aspirin until it reaches the small intestine, which may reduce gastric irritation.
## Primary Indications
* **Antiplatelet therapy:** Prevention of cardiovascular events (e.g., myocardial infarction, stroke) in patients with established cardiovascular disease or risk factors.
* **Analgesia and antipyresis:** For mild to moderate pain and fever. (Note: Enteric-coated aspirin is generally *not* preferred for acute pain/fever due to delayed absorption).
## Adult Dosing
* **Cardiovascular prevention:** Typically 75-100 mg once daily. Doses may vary based on specific guidelines and patient risk.
* **Analgesia/Antipyresis:** Doses vary widely depending on the condition. For antiplatelet use, lower doses are standard. Higher doses (e.g., 325-650 mg every 4-6 hours) may be used for pain/fever, but this formulation is less ideal for rapid symptom relief. Maximum daily dose for antiplatelet therapy is generally 325 mg. For anti-inflammatory effects, much higher doses are required and are typically not achieved with this formulation or for routine use.
## Pediatric Dosing
Aspirin is generally *avoided* in children and adolescents due to the risk of Reye's syndrome, especially during viral illnesses. Specific indications and dosing require careful consideration by a specialist.
## Dose Adjustments
* **Renal Impairment:** Use with caution. Dose reduction may be necessary in severe impairment, though specific guidelines are lacking for enteric-coated formulations.
* **Hepatic Impairment:** Use with caution.
* **Elderly:** Increased risk of gastrointestinal bleeding and other adverse effects; consider lower doses and careful monitoring.
## Contraindications
* Hypersensitivity to aspirin, salicylates, or NSAIDs.
* Active peptic ulcer disease or history of recurrent ulcers.
* Bleeding disorders (e.g., hemophilia, thrombocytopenia).
* Severe hepatic or renal impairment.
* Concurrent use of methotrexate at doses >20 mg/week.
* Children and adolescents with viral infections (risk of Reye's syndrome).
## Adverse Effects
* **Gastrointestinal:** Dyspepsia, nausea, vomiting, abdominal pain, occult bleeding, peptic ulceration, perforation, hemorrhage.
* **Hematologic:** Increased bleeding time, bruising, epistaxis.
* **Hypersensitivity:** Bronchospasm (especially in aspirin-sensitive asthma), urticaria, angioedema.
* **Other:** Tinnitus, dizziness, Reye's syndrome (in children/adolescents).
## Key Drug Interactions
* **Anticoagulants (e.g., warfarin, heparin, DOACs):** Increased risk of bleeding.
* **Other NSAIDs and COX-2 inhibitors:** Additive risk of GI toxicity and bleeding.
* **Corticosteroids:** Increased risk of GI ulceration and bleeding.
* **Antihypertensives (e.g., ACE inhibitors, ARBs, beta-blockers):** NSAIDs may reduce their efficacy.
* **Diuretics:** NSAIDs may reduce diuretic efficacy and increase risk of renal toxicity.
* **Methotrexate:** Increased methotrexate toxicity.
* **Uricosuric agents (e.g., probenecid):** Aspirin may antagonize uricosuric effect.
* **Selective Serotonin Reuptake Inhibitors (SSRIs):** Increased risk of bleeding.
## Monitoring
* **Signs and symptoms of gastrointestinal bleeding:** Melena, hematemesis, abdominal pain.
* **Signs and symptoms of excessive bleeding:** Easy bruising, prolonged bleeding from cuts, epistaxis.
* **Renal and hepatic function:** Especially in patients with pre-existing impairment or those on long-term therapy.
* **Tinnitus:** May indicate salicylate toxicity.
## Clinical Pearls
* The enteric coating delays absorption, making this formulation less suitable for acute pain or fever management where rapid onset is desired.
* Even with enteric coating, gastric irritation and bleeding can still occur, especially with higher doses or prolonged use.
* Patients should be advised to swallow the tablet whole without crushing or chewing to maintain the integrity of the enteric coating.
* Discontinue aspirin at least 5-7 days before elective surgery if feasible and clinically appropriate.
***
*Disclaimer: This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the most current prescribing information and relevant clinical guidelines before making any treatment decisions.*
